APA (7th ed.) Citation

Wass, M., Göllner, S., Besenbeck, B., Schlenk, R. F., Mundmann, P., Göthert, J. R., . . . Müller-Tidow, C. (2021). A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy. Leukemia, 35(3), . https://doi.org/10.1038/s41375-020-0892-z

Chicago Style (17th ed.) Citation

Wass, Maxi, et al. "A Proof of Concept Phase I/II Pilot Trial of LSD1 Inhibition by Tranylcypromine Combined with ATRA in Refractory/relapsed AML Patients Not Eligible for Intensive Therapy." Leukemia 35, no. 3 (2021). https://doi.org/10.1038/s41375-020-0892-z.

MLA (9th ed.) Citation

Wass, Maxi, et al. "A Proof of Concept Phase I/II Pilot Trial of LSD1 Inhibition by Tranylcypromine Combined with ATRA in Refractory/relapsed AML Patients Not Eligible for Intensive Therapy." Leukemia, vol. 35, no. 3, 2021, https://doi.org/10.1038/s41375-020-0892-z.